Clinical trial
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable…
NCT00004060 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00004060 |
|---|---|
| Title | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer |
| Official title | A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane and Topotecan |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | exatecan mesylate |
| Start date | Jul 1, 1999 |
| Primary completion | Sep 1, 2000 |
| Completion | Sep 1, 2000 |
| First posted | Jul 19, 2004 |
| Last update posted | May 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: